• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Atezolizumab and bladder cancer: facing a complex disease.

作者信息

Cattrini Carlo, Boccardo Francesco

机构信息

Academic Unit of Medical Oncology, San Martino Polyclinic Hospital-Institute for Cancer Research and Treatment, 16132 Genoa, Italy; Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genoa, Genoa, Italy.

Academic Unit of Medical Oncology, San Martino Polyclinic Hospital-Institute for Cancer Research and Treatment, 16132 Genoa, Italy; Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genoa, Genoa, Italy.

出版信息

Lancet. 2018 Jan 27;391(10118):305-306. doi: 10.1016/S0140-6736(18)30095-3. Epub 2018 Jan 31.

DOI:10.1016/S0140-6736(18)30095-3
PMID:29413038
Abstract
摘要

相似文献

1
Atezolizumab and bladder cancer: facing a complex disease.阿替利珠单抗与膀胱癌：面对一种复杂的疾病
Lancet. 2018 Jan 27;391(10118):305-306. doi: 10.1016/S0140-6736(18)30095-3. Epub 2018 Jan 31.
2
First-Line Atezolizumab Effective in Bladder Cancer.阿替利珠单抗一线治疗膀胱癌有效。
Cancer Discov. 2016 Aug;6(8):OF7. doi: 10.1158/2159-8290.CD-NB2016-076. Epub 2016 Jun 21.
3
Bladder cancer: Atezolizumab effective against advanced-stage disease.膀胱癌：阿替利珠单抗对晚期疾病有效。
Nat Rev Urol. 2016 May;13(5):238. doi: 10.1038/nrurol.2016.60. Epub 2016 Mar 22.
4
Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.阿替利珠单抗：一种用于膀胱癌的 PD-L1 阻断抗体。
Clin Cancer Res. 2017 Apr 15;23(8):1886-1890. doi: 10.1158/1078-0432.CCR-16-1417. Epub 2016 Nov 30.
5
Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers.阿替利珠单抗：一种用于癌症治疗的新型程序性死亡配体1（PD-L1）抑制剂，重点用于膀胱癌和非小细胞肺癌。
Drugs Today (Barc). 2017 Apr;53(4):217-237. doi: 10.1358/dot.2017.53.4.2589163.
6
[Atezolizumab (Tecentriq): Activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma].[阿替利珠单抗（泰圣奇）：在晚期或转移性膀胱癌中的活性、适应证及使用方式]
Bull Cancer. 2018 Feb;105(2):140-145. doi: 10.1016/j.bulcan.2017.10.030. Epub 2017 Dec 28.
7
Atezolizumab in urothelial bladder carcinoma.阿替利珠单抗治疗尿路上皮膀胱癌。
Future Oncol. 2018 Feb;14(4):331-341. doi: 10.2217/fon-2017-0433. Epub 2017 Nov 14.
8
Atezolizumab (Tecentriq) for bladder cancer and NSCLC.阿替利珠单抗（泰圣奇）用于治疗膀胱癌和非小细胞肺癌。
Med Lett Drugs Ther. 2017 Feb 27;59(1515):e40-e41.
9
Atezolizumab-induced Encephalitis in Metastatic Bladder Cancer: A Case Report and Review of the Literature.阿替利珠单抗诱发的转移性膀胱癌脑炎：一例报告及文献复习
Clin Genitourin Cancer. 2017 Oct;15(5):e847-e849. doi: 10.1016/j.clgc.2017.03.001. Epub 2017 Mar 16.
10
Atezolizumab in invasive and metastatic urothelial carcinoma.阿替利珠单抗用于浸润性和转移性尿路上皮癌
Expert Rev Clin Pharmacol. 2017 Dec;10(12):1295-1301. doi: 10.1080/17512433.2017.1389275. Epub 2017 Oct 30.

引用本文的文献

1
Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.鉴定和验证失调的 TME 相关基因特征，以预测膀胱癌的预后和免疫特性。
Front Immunol. 2023 Oct 27;14:1213947. doi: 10.3389/fimmu.2023.1213947. eCollection 2023.
2
Precision Medicine in Bladder Cancer: Present Challenges and Future Directions.膀胱癌的精准医学：当前挑战与未来方向。
J Pers Med. 2023 Apr 28;13(5):756. doi: 10.3390/jpm13050756.
3
Allosteric activation of the metabolic enzyme GPD1 inhibits bladder cancer growth via the lysoPC-PAFR-TRPV2 axis.
变构激活代谢酶 GPD1 通过溶脂磷脂酸-PAFR-TRPV2 轴抑制膀胱癌生长。
J Hematol Oncol. 2022 Jul 14;15(1):93. doi: 10.1186/s13045-022-01312-5.
4
Medical Image Diagnostic Value of Computed Tomography for Bladder Tumors.计算机断层扫描对膀胱癌的医学影像诊断价值。
Comput Math Methods Med. 2021 Nov 16;2021:3781028. doi: 10.1155/2021/3781028. eCollection 2021.
5
Development and validation of a novel stem cell subtype for bladder cancer based on stem genomic profiling.基于干细胞基因组特征分析，开发并验证膀胱癌新型干细胞亚型。
Stem Cell Res Ther. 2020 Oct 28;11(1):457. doi: 10.1186/s13287-020-01973-4.
6
Chaetocin Abrogates the Self-Renewal of Bladder Cancer Stem Cells via the Suppression of the KMT1A-GATA3-STAT3 Circuit.刺孢霉素通过抑制KMT1A-GATA3-STAT3信号通路消除膀胱癌干细胞的自我更新能力。
Front Cell Dev Biol. 2020 Jun 17;8:424. doi: 10.3389/fcell.2020.00424. eCollection 2020.
7
The lncRNA DLX6-AS1 promoted cell proliferation, invasion, migration and epithelial-to-mesenchymal transition in bladder cancer via modulating Wnt/β-catenin signaling pathway.长链非编码RNA DLX6-AS1通过调节Wnt/β-连环蛋白信号通路促进膀胱癌细胞的增殖、侵袭、迁移及上皮-间质转化。
Cancer Cell Int. 2019 Nov 26;19:312. doi: 10.1186/s12935-019-1010-z. eCollection 2019.
8
The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma.黑色素瘤免疫检查点抑制剂时代急性间质性肾炎的发病机制
Ther Adv Med Oncol. 2019 Sep 24;11:1758835919875549. doi: 10.1177/1758835919875549. eCollection 2019.
9
Hypoxia-elevated circELP3 contributes to bladder cancer progression and cisplatin resistance.低氧上调的 circELP3 促进膀胱癌进展和顺铂耐药性。
Int J Biol Sci. 2019 Jan 1;15(2):441-452. doi: 10.7150/ijbs.26826. eCollection 2019.
10
Mesenchymal glioblastoma constitutes a major ceRNA signature in the TGF-β pathway.间充质胶质母细胞瘤构成 TGF-β 通路中的主要 ceRNA 特征。
Theranostics. 2018 Sep 9;8(17):4733-4749. doi: 10.7150/thno.26550. eCollection 2018.